Full text is available at the source.
Abstract
By 2021, two glucagon-like peptide-1 receptor agonists (GLP-1RAs), semaglutide and liraglutide, received regulatory approval for type 2 diabetes and obesity treatment.
- Concerns have arisen regarding potential differences in adverse events (AEs) between the two GLP-1RAs.
- The distinction in AEs may be influenced by the specific indication for use, either diabetes or obesity.
- Understanding these differences is important for informed treatment decisions and patient safety.
Simplified